An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Vraylar

Chemical Namecariprazine
Dosage FormCapsules (oral; 1.5 mg, 3 mg, 4.5 mg, 6 mg)
Drug ClassAntipsychotics
SystemNervous
CompanyAllergan
Approval Year2015

Indication

  • Treatment of schizophrenia in adults.
  • Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
  • Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.
Last updated on 10/8/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vraylar (cariprazine) Prescribing Information2019Allergan USA, Inc., Madison, NJ
Document TitleYearSource
Cariprazine (Vraylar) for schizophrenia and acute manic or mixed episodes in bipolar I disorder.2016HAYES Inc.
Document TitleYearSource
Cariprazine in the treatment of Bipolar Disorder: A systematic review and meta‐analysis.2019Bipolar Disorders
Use of cariprazine in psychiatric disorders: A systematic review.2018Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
Tolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder and major depressive disorder: a systematic review with meta-analysis of randomized controlled trials.2016CNS Drugs